Unlocking the Full Therapeutic Value of Natural Cell Protection Pathways
OMEICOS Therapeutics is focused on developing therapies that can have a significant impact on cardiovascular and inflammatory diseases, in ophthalmology and other therapeutic areas. Our pipeline is based on our proprietary approach to target one of nature’s most important cell-protective pathways and industry-leading knowledge of omega-3 fatty acid metabolism and biology.
OMEICOS lead compound, OMT-28, has most recently advanced into a double-blinded, placebo-controlled, multi-center Phase 2 clinical trial in patients suffering from Atrial Fibrillation – less than 6 years after founding the company in Berlin. The trial is aimed at establishing a robust clinical proof-of-concept and a ready to Phase 3 package for a fast transition into pivotal trials.
Beyond Atrial Fibrillation, the company is establishing a broader pipeline with initial work focusing on other cardiovascular conditions and ophthalmological indications, the latter driven by the US-based subsidiary OMEICOS Ophthalmics.